Saturday 17 October 2026
Export TNON’s income statement to Excel — free account
Tenon Medical, Inc.
TNON Healthcare Medical Devices
Tenon Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 126.8%, EPS grew 1.88% and free cash flow fell 21.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.70
0.21
−7.22%
Follow TNON
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 6 | 4 | 5 | 6 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (8.17) | (19.42) | (12.93) | (13.00) |
P/S ratio |
116.67 | 116.67 | 116.67 | 18.68 | 0.96 | 0.70 | 1.78 |
Altman Z″-Score (non-manufacturers) |
(110.23) | (67.84) | (17.74) | (17.57) | (44.03) | (26.32) | (29.53) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(10.23) | (10.23) | (10.23) | (3.81) | (1.24) | (0.82) | (3.16) |
Beneish M-Score |
— | (9.71) | (1.46) | — | (3.76) | (3.89) | (1.81) |
P/B ratio |
0.00 | 0.00 | 0.00 | 2.07 | 3.63 | 1.03 | 3.58 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 2.07 | 3.63 | 1.03 | 0.00 |
EV/Sales |
96.56 | 96.56 | 96.56 | 6.77 | 0.25 | (1.20) | 0.92 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 |
EV/Operating CF |
(3.16) | (3.16) | (3.16) | (0.39) | (0.06) | 0.40 | (0.34) |
EV/FCF |
(3.06) | (3.06) | (3.06) | (0.36) | (0.06) | 0.39 | (0.31) |
Quick Ratio |
0.12 | 0.17 | 0.48 | 3.48 | 0.94 | 3.96 | 1.70 |
Current Ratio |
0.16 | 0.20 | 0.50 | 3.69 | 1.24 | 4.39 | 2.11 |
Net Debt/EBITDA |
(1.45) | (0.16) | 1.15 | 0.46 | 0.16 | 0.50 | 0.31 |
Debt/Assets |
345.55% | 85.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.36) | (0.16) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.13 | 0.03 | 0.07 | 0.34 | 0.40 | 0.38 |
Operating CF/Net income |
0.46 | 0.29 | 0.61 | 0.64 | 0.78 | 0.72 | 0.86 |
Capex/Depreciation |
— | — | (0.89) | (2.93) | (0.85) | (0.28) | (1.93) |
Interest Coverage |
(20.36) | (3.20) | (10.40) | (52.90) | (748.90) | (404.88) | — |
| 0.00% | 16.06% | 58.83% | 264.57% | (443.27%) | (912.45%) | (600.05%) | |
| 0.00% | (177.49%) | (145.88%) | (185.82%) | (178.74%) | (168.93%) | (121.89%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (622.66%) |
Return on Tangible Assets |
35.87% | 49.14% | 93.96% | (248.58%) | (911.17%) | (192.77%) | (280.71%) |
Average Days of Receivables |
366.36 | 120.83 | 173.38 | 120.43 | 64.57 | 96.12 | 157.14 |
Research and Development Expense of Revenue |
693.10% | 504.34% | 1,073.75% | 409.26% | 108.03% | 79.43% | 54.49% |
Selling, General and Administrative Expense of Revenue |
368.10% | 778.54% | 3,030.00% | 2,207.81% | 471.48% | 392.86% | 329.64% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 |
Share Based Compensation of Revenue |
0.00% | 37.90% | 235.63% | 419.25% | 141.56% | 117.33% | 42.88% |
Graham Net Nets |
(0.43) | (0.43) | (0.43) | 0.35 | (0.59) | 1.90 | 0.15 |
Graham Number |
0.00 | 0.00 | 183,875.17 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(44.31%) | (44.31%) | (44.31%) | (251.95%) | (627.76%) | (597.68%) | (208.82%) |
Free Cash Flow Yield |
(27.08%) | (27.08%) | (27.08%) | (99.70%) | (444.67%) | (440.77%) | (166.70%) |
Revenue per Share |
0.05 | 146.00 | 533.33 | 238.28 | 450.46 | 94.44 | 18.67 |
Operating CF per Share |
(0.21) | (558.00) | (14,306.67) | (4,146.55) | (1,874.31) | (284.67) | (50.88) |
Capex per Share |
0.00 | 0.00 | (340.00) | (292.07) | (55.54) | (5.36) | (4.84) |
Free Cash Flow per Share |
(0.21) | (558.00) | (14,646.67) | (4,438.62) | (1,929.85) | (290.03) | (55.72) |
Cash per Share |
0.14 | 818.67 | 24,403.33 | 2,955.17 | 373.54 | 188.33 | 17.78 |
Shareholders Equity per Share |
(2.32) | (7,123.00) | (23,043.33) | 2,155.86 | 119.69 | 172.07 | 23.86 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.32) | (7,123.00) | (23,043.33) | 2,155.86 | 119.69 | 172.07 | 23.86 |
Free Cash Flow |
(0.24) | (0.17) | (4.39) | (12.87) | (12.54) | (10.06) | (11.77) |
Working Capital |
(1.42) | (1.19) | (7.60) | 6.82 | 0.75 | 6.34 | 3.56 |
Capital Expenditures |
— | — | (0.10) | (0.85) | (0.36) | (0.19) | (1.02) |
Net Current Asset Value |
(1.61) | (1.52) | (8.51) | 4.51 | (1.68) | 4.34 | 1.05 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.64 | 1.23 | 0.12 | 0.06 | 0.26 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
— | — | 1.13 | 0.36 | 0.44 | 0.87 | 0.58 |
Cash ROIC |
15.38% | 10.75% | (1,076.96%) | (86.84%) | (391.27%) | (80.47%) | (133.79%) |
Accounts Receivable Turnover |
0.00 | 1.28 | 3.54 | 4.55 | 7.85 | 4.75 | 3.08 |
Accounts Payable Turnover |
0.00 | 0.04 | 0.10 | 2.59 | 3.43 | 3.91 | 2.61 |
Inventory Turnover |
0.00 | 0.35 | 0.48 | 4.42 | 3.48 | 2.70 | 1.91 |
Average Days of Payables |
8,925.55 | 11,751.80 | 3,172.18 | 150.71 | 93.68 | 86.01 | 194.47 |
Days of Inventory on Hand |
1,226.64 | 863.63 | 1,247.64 | 113.72 | 119.86 | 141.25 | 242.57 |
Average Receivables |
— | 0.03 | 0.05 | 0.15 | 0.37 | 0.69 | 1.28 |
Average Payables |
— | 0.52 | 0.53 | 0.51 | 0.49 | 0.40 | 0.61 |
Average Inventory |
— | 0.05 | 0.12 | 0.30 | 0.48 | 0.58 | 0.83 |
Average Assets |
— | 0.33 | 4.83 | 10.18 | 8.72 | 8.09 | 10.30 |
Average Common Equity |
— | (3.64) | (11.98) | (7.15) | 3.52 | 1.50 | 2.09 |
Columns are period end dates